EXPLORE-RCC
Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis
- NCT06794229 ↗
- Recruiting
- Qian Qin
- Focused
We haven't built an HCP commentary report on EXPLORE-RCC (zanzalintinib plus nivolumab in locally advanced/inoperable clear cell renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EXPLORE-RCC so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Open-label, Single-arm Study of nEoadjuvant Zanzalintinib (XL092) Plus nivoLumab in Patients With lOcally Advanced and/or inopeRable clEar Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis (EXPLORE-RCC)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Locally Advanced Renal Cell Carcinoma
- Interventions
- Zanzalintinib; Nivolumab
- Arms
- Zanzalintinib (XL092) and Nivolumab · Experimental
- Enrollment
- 69 (estimated)
- Primary outcomes
- Objective response rate (ORR)
- Sponsor
- Qian Qin with Exelixis, University of Texas
- Start
- Oct 30, 2025
- Primary completion
- Jun 6, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06794229 · updated Sep 4, 2026